Statement Of Cash Flows [Abstract]

Xbrane Biopharma - Filing #679208

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Income taxes paid (refund), classified as operating activities
SEK
SEK
Cash flows from (used in) operating activities
406 678 SEK
193 918 SEK
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities
6 791 SEK
11 616 SEK
Purchase of intangible assets, classified as investing activities
9 978 SEK
48 509 SEK
Cash flows from (used in) investing activities
16 769 SEK
60 125 SEK
Cash flows from (used in) financing activities [abstract]
Proceeds from changes in ownership interests in subsidiaries that do not result in loss of control
18,000 SEK
551,000 SEK
Proceeds from issuing shares
120 000 SEK
170 000 SEK
Proceeds from borrowings, classified as financing activities
225 000 SEK
SEK
Repayments of borrowings, classified as financing activities
20 833 SEK
SEK
Payments of lease liabilities, classified as financing activities
13 909 SEK
8 337 SEK
Cash flows from (used in) financing activities
298 696 SEK
148 864 SEK
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
124 752 SEK
105 179 SEK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
4 485 SEK
4 046 SEK
Cash and cash equivalents
65 402 SEK
193 994 SEK
295 180 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.